keyword
MENU ▼
Read by QxMD icon Read
search

Weiss, pamela

keyword
https://www.readbyqxmd.com/read/28916542/comparative-effectiveness-of-tumor-necrosis-factor-agents-and-disease-modifying-antirheumatic-therapy-in-children-with-enthesitis-related-arthritis-the-first-year-after-diagnosis
#1
Pamela F Weiss, Rui Xiao, Timothy G Brandon, Ilaria Pagnini, Tracey B Wright, Timothy Beukelman, Esi Morgan-DeWitt, Chris Feudtner
OBJECTIVE: To characterize the effect of anti-tumor necrosis factor (TNF) therapy compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in children with enthesitis-related arthritis (ERA) over the first year after diagnosis. METHODS: We conducted a multicenter retrospective comparative effectiveness study of children diagnosed with ERA. We estimated the effect of anti-TNF therapy on clinical variables (active joint count, tender entheses count) and patient-reported pain and global assessment of disease activity over the first year after diagnosis using state-of-the-art comparative effectiveness analytic methods...
September 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28464909/multicenter-inception-cohort-of-enthesitis-related-arthritis-variation-in-disease-characteristics-and-treatment-approaches
#2
Sabrina Gmuca, Rui Xiao, Timothy G Brandon, Ilaria Pagnini, Tracey B Wright, Timothy Beukelman, Esi M Morgan, Pamela F Weiss
BACKGROUND: Enthesitis-related arthritis (ERA) is a specific subtype of juvenile idiopathic arthritis (JIA) defined according to the International League of Associations for Rheumatology (ILAR) criteria. We aimed to characterize the clinical features and treatment regimens in an inception cohort of children with ERA. METHODS: We performed a retrospective, cross-sectional, multicenter cohort study including subjects diagnosed with ERA between 1989 and 2012. Patients all fulfilled the ILAR criteria for ERA within 3 months of initial presentation to the rheumatology clinic...
May 2, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28399931/pilot-study-comparing-the-childhood-arthritis-rheumatology-research-alliance-carra-systemic-juvenile-idiopathic-arthritis-consensus-treatment-plans
#3
COMPARATIVE STUDY
Yukiko Kimura, Sriharsha Grevich, Timothy Beukelman, Esi Morgan, Peter A Nigrovic, Kelly Mieszkalski, T Brent Graham, Maria Ibarra, Norman Ilowite, Marisa Klein-Gitelman, Karen Onel, Sampath Prahalad, Marilynn Punaro, Sarah Ringold, Dana Toib, Heather Van Mater, Jennifer E Weiss, Pamela F Weiss, Laura E Schanberg
OBJECTIVES: To assess the feasibility of studying the comparative effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus treatment plans (CTPs) for systemic Juvenile Idiopathic Arthritis (JIA) using an observational registry. METHODS: Untreated systemic JIA patients enrolled in the CARRA Registry were begun on one of 4 CTPs chosen by the treating physician and patient/family (glucocorticoid [GC] alone; methotrexate [MTX] ± GC; IL1 inhibitor [IL1i] ± GC; IL6 inhibitor [IL6i] ± GC)...
April 11, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28260573/pamela-donovan-drink-spiking-and-predatory-drugging-a-modern-history-new%C3%A2-york-palgrave-macmillan-2016-pp-%C3%A2-294-99-00-hardback-isbn-%C3%A2-9-781137-575166
#4
https://www.readbyqxmd.com/read/28129483/association-of-anti-3-hydroxy-3-methylglutaryl-coenzyme-a-reductase-autoantibodies-with-drb1-07-01-and-severe-myositis-in-juvenile-myositis-patients
#5
Takayuki Kishi, Lisa G Rider, Katherine Pak, Lilliana Barillas-Arias, Michael Henrickson, Paul L McCarthy, Bracha Shaham, Pamela F Weiss, Iren Horkayne-Szakaly, Ira N Targoff, Frederick W Miller, Andrew L Mammen
OBJECTIVE: Autoantibodies recognizing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are associated with statin exposure, the HLA allele DRB1*11:01, and necrotizing muscle biopsies in adult myositis patients. The aim of this study was to characterize the features of juvenile anti-HMGCR-positive myositis patients. METHODS: The sera of 440 juvenile myositis patients were screened for anti-HMGCR autoantibodies. Demographic and clinical features, responses to therapy, and HLA alleles were assessed...
July 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28029918/activity-of-selumetinib-in-neurofibromatosis-type-1-related-plexiform-neurofibromas
#6
Eva Dombi, Andrea Baldwin, Leigh J Marcus, Michael J Fisher, Brian Weiss, AeRang Kim, Patricia Whitcomb, Staci Martin, Lindsey E Aschbacher-Smith, Tilat A Rizvi, Jianqiang Wu, Rachel Ershler, Pamela Wolters, Janet Therrien, John Glod, Jean B Belasco, Elizabeth Schorry, Alessandra Brofferio, Amy J Starosta, Andrea Gillespie, Austin L Doyle, Nancy Ratner, Brigitte C Widemann
BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elevated RAS-mitogen-activated protein kinase (MAPK) signaling. METHODS: We conducted a phase 1 trial of selumetinib (AZD6244 or ARRY-142886), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maximum tolerated dose and to evaluate plasma pharmacokinetics...
December 29, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27822769/imaging-in-juvenile-spondyloarthritis
#7
REVIEW
Pamela F Weiss, Nancy A Chauvin, Johannes Roth
PURPOSE OF REVIEW: This review aims to provide an update on the use of imaging in the assessment of juvenile spondyloarthritis (JSpA) disease manifestations. RECENT FINDINGS: Recent studies have demonstrated superior reliability and specificity of MRI for assessment of sacroiliac joint inflammation compared with radiography. The use of gadolinium contrast may not add incremental value to the assessment of inflammatory sacroiliitis. Sacroiliitis is common at diagnosis of spondyloarthritis...
December 2016: Current Rheumatology Reports
https://www.readbyqxmd.com/read/27813340/variation-in-the-treatment-of-children-hospitalized-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis-in-the-us
#8
Karen E James, Rui Xiao, Peter A Merkel, Pamela F Weiss
OBJECTIVE: There are few reports on the treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) in children. This study characterizes the use of cyclophosphamide, rituximab, and plasma exchange in children hospitalized with AAV in the US. METHODS: We conducted a retrospective cohort study of children hospitalized with AAV from 2004-2014 utilizing an administrative and billing database from 47 tertiary care pediatric hospitals. All patients had an International Classification of Diseases, Ninth Revision, Clinical Modification discharge code of 446...
September 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/27749233/clinical-course-and-outcomes-of-childhood-onset-granulomatosis-with-polyangiitis
#9
Karen E James, Rui Xiao, Peter A Merkel, Pamela F Weiss
OBJECTIVES: To characterise the clinical course and outcomes of a cohort of children with granulomatosis with polyangiitis (GPA). METHODS: Retrospective cohort study of children diagnosed with GPA in a tertiary care facility from 2000-2014. All subjects met the American College of Rheumatology 1990 criteria for GPA or the 2008 European League against Rheumatism/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society criteria for GPA...
March 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27742028/imaging-enhanced-evaluation-of-children-and-adults-with-rheumatic-disease
#10
EDITORIAL
Pamela F Weiss
No abstract text is available yet for this article.
November 2016: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/27632680/cytokine-release-syndrome-after-chimeric-antigen-receptor-t-cell-therapy-for-acute-lymphoblastic-leukemia
#11
Julie C Fitzgerald, Scott L Weiss, Shannon L Maude, David M Barrett, Simon F Lacey, J Joseph Melenhorst, Pamela Shaw, Robert A Berg, Carl H June, David L Porter, Noelle V Frey, Stephan A Grupp, David T Teachey
OBJECTIVE: Initial success with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through multicenter trials. Cytokine release syndrome, the most severe toxicity, presents a novel critical illness syndrome with limited data regarding diagnosis, prognosis, and therapy. We sought to characterize the timing, severity, and intensive care management of cytokine release syndrome after chimeric antigen receptor-modified T cell therapy...
February 2017: Critical Care Medicine
https://www.readbyqxmd.com/read/27607024/systemic-onset-juvenile-idiopathic-arthritis-and-exposure-to-fine-particulate-air-pollution
#12
MULTICENTER STUDY
Andrew S Zeft, Sampath Prahalad, Rayfel Schneider, Fatma Dedeoglu, Pamela F Weiss, Alexei A Grom, Carter Mix, C Arden Pope Rd
OBJECTIVES: Fine particulate matter (PM2.5) is a measurable component of ambient pollution, and positive associations of short-term PM2.5 exposure with the clinical presentation of systemic onset juvenile idiopathic arthritis (SJIA) in young children have been described in a regional cohort. Our objective was to further establish associations between short-term pollution exposures and the reported clinical event of SJIA onset in cases residing from multiple metropolitan regions. METHODS: A case-crossover study design was used to analyse associations of short-term PM2...
September 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27513339/the-effect-of-protandim%C3%A2-supplementation-on-athletic-performance-and-oxidative-blood-markers-in-runners
#13
RANDOMIZED CONTROLLED TRIAL
Seteena L Ueberschlag, James R Seay, Alexandra H Roberts, Pamela C DeSpirito, Jeremy M Stith, Rodney J Folz, Kathleen A Carter, Edward P Weiss, Gerald S Zavorsky
UNLABELLED: The purpose of this study determined if oral supplementation of Protandim® (a nutraceutical) for 90 days improved 5-km running performance and reduced serum thiobarbituric acid-reacting substances (TBARS) at rest, an indicator of oxidative stress. Secondary objectives were to measure whole blood superoxide dismutase (SOD), glutathione (GSH), and glutathione peroxidase (GPX), at rest and 10 minutes after completion of the race before and after supplementation as well as quality of life...
2016: PloS One
https://www.readbyqxmd.com/read/27466726/update-on-enthesitis-related-arthritis
#14
REVIEW
Pamela F Weiss
PURPOSE OF REVIEW: This review provides a detailed update regarding the genetics, pathogenesis, disease phenotype evaluation, therapies and expected outcomes for children with enthesitis-related arthritis (ERA). RECENT FINDINGS: Recent studies evaluated human leukocyte antigen (HLA)-B27 subtypes and non-major histocompatibility complex genes including toll like receptor 4, NLRP3, CXCR4 and PTPN12 in children with ERA. The microbiome and γδ-T cells have also been an area of active investigation...
September 2016: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/27399676/protonation-sites-tandem-mass-spectrometry-and-computational-calculations-of-o-carbonyl-carbazolequinone-derivatives
#15
Maximiliano Martínez-Cifuentes, Graciela Clavijo-Allancan, Pamela Zuñiga-Hormazabal, Braulio Aranda, Andrés Barriga, Boris Weiss-López, Ramiro Araya-Maturana
A series of a new type of tetracyclic carbazolequinones incorporating a carbonyl group at the ortho position relative to the quinone moiety was synthesized and analyzed by tandem electrospray ionization mass spectrometry (ESI/MS-MS), using Collision-Induced Dissociation (CID) to dissociate the protonated species. Theoretical parameters such as molecular electrostatic potential (MEP), local Fukui functions and local Parr function for electrophilic attack as well as proton affinity (PA) and gas phase basicity (GB), were used to explain the preferred protonation sites...
July 5, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27159889/patient-reported-outcomes-measurement-information-system-tools-for-collecting-patient-reported-outcomes-in-children-with-juvenile-arthritis
#16
COMPARATIVE STUDY
Timothy G Brandon, Brandon D Becker, Katherine B Bevans, Pamela F Weiss
OBJECTIVE: To evaluate the precision and construct validity of pediatric Patient-Reported Outcomes Measurement Information System (PROMIS) instruments in a population of juvenile idiopathic arthritis (JIA) patients and parent proxies. METHODS: A convenience sample of JIA patients and parents of JIA patients completed PROMIS instruments for 8 domains: anger, anxiety, depressive symptoms, fatigue, mobility, pain interference, peer relationships, and upper-extremity function...
March 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/27076371/identification-of-predictive-biomarkers-for-cytokine-release-syndrome-after-chimeric-antigen-receptor-t-cell-therapy-for-acute-lymphoblastic-leukemia
#17
David T Teachey, Simon F Lacey, Pamela A Shaw, J Joseph Melenhorst, Shannon L Maude, Noelle Frey, Edward Pequignot, Vanessa E Gonzalez, Fang Chen, Jeffrey Finklestein, David M Barrett, Scott L Weiss, Julie C Fitzgerald, Robert A Berg, Richard Aplenc, Colleen Callahan, Susan R Rheingold, Zhaohui Zheng, Stefan Rose-John, Jason C White, Farzana Nazimuddin, Gerald Wertheim, Bruce L Levine, Carl H June, David L Porter, Stephan A Grupp
UNLABELLED: Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS...
June 2016: Cancer Discovery
https://www.readbyqxmd.com/read/27008869/gwas-meta-analysis-of-16-852-women-identifies-new-susceptibility-locus-for-endometrial-cancer
#18
Maxine M Chen, Tracy A O'Mara, Deborah J Thompson, Jodie N Painter, John Attia, Amanda Black, Louise Brinton, Stephen Chanock, Chu Chen, Timothy Ht Cheng, Linda S Cook, Marta Crous-Bou, Jennifer Doherty, Christine M Friedenreich, Montserrat Garcia-Closas, Mia M Gaudet, Maggie Gorman, Christopher Haiman, Susan E Hankinson, Patricia Hartge, Brian E Henderson, Shirley Hodgson, Elizabeth G Holliday, Pamela L Horn-Ross, David J Hunter, Loic Le Marchand, Xiaolin Liang, Jolanta Lissowska, Jirong Long, Lingeng Lu, Anthony M Magliocco, Lynn Martin, Mark McEvoy, Sara H Olson, Irene Orlow, Loreall Pooler, Jennifer Prescott, Radhai Rastogi, Timothy R Rebbeck, Harvey Risch, Carlotta Sacerdote, Frederick Schumacher, Veronica Wendy Setiawan, Rodney J Scott, Xin Sheng, Xiao-Ou Shu, Constance Turman, David Van Den Berg, Zhaoming Wang, Noel S Weiss, Nicholas Wentzensen, Lucy Xia, Yong-Bing Xiang, Hannah P Yang, Herbert Yu, Wei Zheng, Paul D P Pharoah, Alison M Dunning, Ian Tomlinson, Douglas F Easton, Peter Kraft, Amanda B Spurdle, Immaculata De Vivo
Endometrial cancer is the most common gynecological malignancy in the developed world. Although there is evidence of genetic predisposition to the disease, most of the genetic risk remains unexplained. We present the meta-analysis results of four genome-wide association studies (4907 cases and 11 945 controls total) in women of European ancestry. We describe one new locus reaching genome-wide significance (P < 5 × 10 (-)(8)) at 6p22.3 (rs1740828; P = 2.29 × 10 (-)(8), OR = 1.20), providing evidence of an additional region of interest for genetic susceptibility to endometrial cancer...
June 15, 2016: Human Molecular Genetics
https://www.readbyqxmd.com/read/26824032/evaluation-and-treatment-of-childhood-enthesitis-related-arthritis
#19
Sabrina Gmuca, Pamela F Weiss
No abstract text is available yet for this article.
December 2015: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/26624007/can-cd44-be-a-mediator-of-cell-destruction-the-challenge-of-type-1-diabetes
#20
Nathalie Assayag-Asherie, Dror Sever, Marika Bogdani, Pamela Johnson, Talya Weiss, Ariel Ginzberg, Sharon Perles, Lola Weiss, Lora Eshkar Sebban, Eva A Turley, Elimelech Okon, Itamar Raz, David Naor
CD44 is a multi-functional receptor with multiple of isoforms engaged in modulation of cell trafficking and transmission of apoptotic signals. We have previously shown that injection of anti-CD44 antibody into NOD mice induced resistance to type 1 diabetes (T1D). In this communication we describe our efforts to understand the mechanism underlying this effect. We found that CD44-deficient NOD mice develop stronger resistance to T1D than wild-type littermates. This effect is not explained by the involvement of CD44 in cell migration, because CD44-deficient inflammatory cells surprisingly had greater invasive potential than the corresponding wild type cells, probably owing to molecular redundancy...
2015: PloS One
keyword
keyword
10117
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"